(±)-U-50488 hydrochloride

Biological Activity

(-)-enantiomer and (+)-enantiomer also available.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Additional Information

Background References

1. Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells.
   Kharmate G, Rajput P, Lin Y, Kumar U
   Cancer Cell Int, 2013;13(1):93.
2. Development of functionally selective, small molecule agonists at kappa opioid receptors.
   Zhou L, Lovell K, Frankowski K, Slauson S, Phillips A, Streicher J, Stahl E, Schmid C, Hodder P, Madoux F, Cameron M, Prisinzano T, Aube J, Bohn L
   J Biol Chem, 2013;288(51):36703-16.
3. High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death.
   Fox JT, Sakamuru S, Huang R
   Proc. Natl. Acad. Sci. U.S.A., 2012;109(14):5423-8.
4. Cardiovascular actions of the κ-agonist, U-50-488H, in the absence and presence of opioid receptor blockade.
   Pugsley et al.
   Br.J.Pharmacol., 1992;105:521
5. U-50,488 blocks the development of mor. tolerance and dependence at a very low dose in guinea pigs.
   Pao-Luh Tao et al.
   Eur.J.Pharmacol., 1994;256:281
6. Activation of kappa opioid receptors by U-50488H and mor. enhances the release of substance P from rat trigeminal nucleus slices.
   Suarez-Roca and Maixner
   J.Pharmacol.Exp.Ther., 1993;264:648
7. Blockade of the development of mor. tolerance by U-50,488, an AVP antagonist or MK 801 in the rat hippocampal slice.
   Su et al.
   Br.J.Pharmacol., 1998;123:625

Product Datasheets